Junshi Biology and the Institute of Microbiology, Chinese Academy of Sciences announce cooperation to develop Zika virus vaccine

Shanghai, October 8, 2021/PRNewswire/ - On October 8, 2021 Beijing time, Junshi Bio (1877.

Zika virus is a type of mosquito-borne flavivirus.

Currently, no Zika vaccine product has been approved for use worldwide

Since 2016, Gao Fu, an academician of the Chinese Academy of Sciences and a researcher of the Institute of Microbiology of the Chinese Academy of Sciences, has led a team to conduct research on Zika virus

As a leading domestic innovative pharmaceutical company, Junshi Biotechnology has established a long-term cooperation with the Institute of Microbiology of the Chinese Academy of Sciences with its own complete antibody development platform to carry out research and development work on the screening of various pathogen host receptors and anti-pathogen antibodies for rehabilitation patients

Dr.

[1] Science, 369, 1123–1128 (2020)

[2] Dai, L.

About Junshi Bio

Junshi Bio (688180.

Relying on the protein engineering core platform technology, Junshi Bio is at the forefront of international macromolecular drug research and development, and has obtained the first domestic anti-PD-1 monoclonal antibody NMPA approval, the domestic anti-PCSK9 monoclonal antibody NMPA clinical application approval, and the world's first treatment The tumor anti-BTLA blocking antibody was approved by the Chinese NMPA and the US FDA for clinical application, and the phase I clinical study was conducted in China and the United States

About the Institute of Microbiology, Chinese Academy of Sciences

The Institute of Microbiology, Chinese Academy of Sciences was established on December 3, 1958.

Source: Junshi Bio